Gene Therapy vs Standard Treatment — Clinical Trial Comparison
Gene Therapy
Modifying genes to treat or cure disease at the DNA level
VS
Standard Treatment
Established pharmacological, surgical, or supportive approaches
Gene therapy represents a paradigm shift in medicine — rather than managing symptoms or fighting disease with drugs, it aims to correct the underlying genetic cause. UK clinical trials are pioneering gene therapy across haemophilia, sickle cell disease, inherited retinal disorders, and neurological conditions. Comparing gene therapy trials with standard treatment trials helps patients understand the emerging landscape and make informed decisions about participating.
Key Differences at a Glance
| Feature | Gene Therapy | Standard Treatment |
|---|---|---|
| Mechanism | Delivers, edits, or silences genes to treat disease at the molecular root cause | Manages disease through drugs, surgery, or supportive care without altering genetics |
| Potential for cure | One-time curative potential (especially for monogenic diseases) | Usually ongoing management rather than cure |
| Treatment delivery | Viral vectors (AAV, lentivirus), CRISPR-Cas9, RNA-based, ex vivo cell modification | Oral medications, IV infusions, injections, surgery, physiotherapy |
| Time to effect | Weeks to months; durable if successful | Variable — often immediate symptom management |
| Key conditions in trials | Haemophilia A/B, sickle cell disease, thalassaemia, inherited retinal disorders, muscular dystrophy, Parkinson's | Virtually all conditions — the established standard of care |
| Regulatory status | Most still experimental; a few approved (Libmeldy, Casgevy, Hemgenix) | Well-established regulatory pathways and NICE approval |
Clinical Trial Availability
| Trial Aspect | Gene Therapy | Standard Treatment |
|---|---|---|
| UK trials actively recruiting | 80–150 studies | Thousands across all conditions |
| Most common phases | Phase 1–2 (early stage) | Phase 2–4 (later stages) |
| Top conditions in trials | Haemophilia, sickle cell, retinal diseases, neuromuscular, rare metabolic | All common conditions — cancer, cardiovascular, respiratory, etc. |
| Trial size | Small cohorts (10–50 patients) due to novelty and cost | Large cohorts (hundreds to thousands) |
| Duration of follow-up | Long-term (5–15 years monitoring for durability and safety) | Variable — often 1–5 years |
| Manufacturing complexity | Highly complex — individualised or small-batch production | Standard pharmaceutical manufacturing |
Exciting Emerging Treatments
Gene Therapy Trials
- CRISPR-Cas9 gene editing — precise DNA modification (Casgevy for sickle cell)
- Base editing and prime editing — even more precise than standard CRISPR
- AAV gene therapy — viral delivery for haemophilia, retinal disorders, muscular dystrophy
- RNA-based therapies — gene silencing, antisense oligonucleotides, RNA editing
- In vivo gene editing — editing genes directly inside the body
- Gene therapy for common diseases — expanding beyond rare diseases to heart failure, Parkinson's
Standard Treatment Trials
- Biologics and biosimilars — expanding access to biological medicines
- Digital therapeutics — app-based and software-driven treatments
- Personalised medicine — tailoring standard treatments to genetic profiles
- Minimally invasive surgery — robotic and endoscopic advances
- Combination approaches — standard + novel therapies in optimised regimens
- Real-world evidence trials — learning from routine clinical practice
💡 Not sure which trials you qualify for?
Use our Smart Matcher to answer a few questions about your condition and we'll find the most relevant trials for your specific situation — free, instant results.
Eligibility Differences
Gene Therapy Trial Criteria
- Confirmed genetic diagnosis matching the therapy target
- Specific genetic variant required (e.g., FVIII deficiency for haemophilia A gene therapy)
- No pre-existing immunity to viral vector (AAV antibodies tested)
- Adequate organ function for procedure
- Often restricted to adults or specific age ranges
- Willingness for long-term follow-up (5–15 years)
Standard Treatment Trial Criteria
- Confirmed clinical diagnosis appropriate for the treatment
- Failed or intolerant of prior standard therapies (for many trials)
- Measurable disease or symptoms
- Adequate organ function and performance status
- No contraindications to the study treatment
- Age and comorbidity criteria met
Gene Therapy Trials
Find actively recruiting gene therapy clinical trials across the UK
Gene Therapy TrialsFrequently Asked Questions
Is gene therapy a one-time treatment?
Most gene therapies are designed to be one-time treatments that provide long-lasting or permanent effect. For example, haemophilia gene therapy aims to enable the body to produce its own clotting factor for years. However, long-term durability is still being studied, and some patients may need retreatment.
Why are gene therapy trials so small?
Gene therapy trials are small because the treatments are highly personalised, manufacturing is complex and expensive, and regulatory requirements for novel genetic medicines are rigorous. Early-phase trials focus on safety and proof-of-concept with small groups before expanding.
Can gene therapy be combined with standard treatment?
Yes — increasingly so. Some trials use gene therapy alongside standard treatments, for example using gene-edited cells in combination with immunotherapy for cancer, or gene therapy to enhance the effectiveness of enzyme replacement therapy.